 "claris")
Ahmedabad-headquartered Claris Lifesciences that recently completed the sale of its remaining 20 per cent stake in Otsuka Pharmaceutical India Private Limited (OPIPL), the joint venture with Otsuka Pharmaceutical Factory and Mitsui & Co, to Otsuka, on Thursday said that it is considering options (dividend or share buyback) to distribute around Rs 2,077 crore to its shareholders.
In a filing to the BSE, Claris Lifesciences said that the total cash available with the company is Rs 3,614 crore. In the company's Board meeting today, the Board has approved various expenses and costs aggregating to Rs 1,537 crore relating to various
In a filing to the BSE, Claris Lifesciences said that the total cash available with the company is Rs 3,614 crore. In the company's Board meeting today, the Board has approved various expenses and costs aggregating to Rs 1,537 crore relating to various
